Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients

Paraskevi Karousi, BSc, Aristea-Maria Papanota, MD, Pinelopi I Artemaki, BSc, Christine Liacos, MSc, Christos K. Kontos, PhD, Dimitris Patseas, BSc, Aikaterini-Anna Liosi, BSc, Nefeli Mavrianou-Koutsoukou, BSc, Maria-Anna Kalioraki, BSc, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Magdalini Migkou, MD, Panagiotis Malandrakis, MD, Maria Gavriatopoulou, MD, Eftathios Kastritis, Evangelos Terpos, MD PhD, Andreas Scorilas, PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 5528.

https://doi.org/10.1182/blood-2019-129082

Published: 2019

Journal Articles

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Pinelopi I Artemaki, BSc, Aristea-Maria Papanota, MD, Paraskevi Karousi, BSc, Christine Liacos, MSc, Christos K. Kontos, PhD, Dimitris Patseas, BSc, Maria-Alexandra Papadimitriou, BSc, Evangelos Eleutherakis-Papaiakovou, MD, Margaritis Avgeris, PhD, Nikolaos Kanellias, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Ioanna Dialoupi, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Meletios A. Dimopoulos, MD, Andreas Scorilas, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 5529.

https://doi.org/10.1182/blood-2019-129218

Published: 2019

Journal Articles

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Saurabh Mishra, MD DNB, Ashok K Vaid, MDDM, Nitin Sood, MDFRCPath,MRCP, Manorama Bhargava, Bhuvan Chugh, DNB, Roshan Dixit, MD, Amrita Ramaswami, MDDM, Devender Sharma, MD

Blood (2019) 134 (Supplement_1): 5559.

https://doi.org/10.1182/blood-2019-125752

Published: 2019

Journal Articles

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Sandro Bräunig, MSc, Dimitra Zacharaki, PhD, Hongzhe Li, PhD, Hooi Ching Lim, PhD, Stefan Lang, PhD, Thoas Fioretos, MD PhD Prof., Stefan Scheding, MD

Blood (2019) 134 (Supplement_1): 4373.

https://doi.org/10.1182/blood-2019-128024

Published: 2019

Journal Articles

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3165.

https://doi.org/10.1182/blood-2019-124370

Published: 2019

Journal Articles

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Salmon Manier, Meletios A. Dimopoulos, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Michel Delforge, Katja C. Weisel, MD, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Bruno Costa, Suzanne Robinson, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 3122.

https://doi.org/10.1182/blood-2019-124557

Published: 2019

Journal Articles

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Elena Zamagni, MD, Sujith Dhanasiri, Adam Moore, Arun Ghale, Murielle Roussel, MD

Blood (2019) 134 (Supplement_1): 4772.

https://doi.org/10.1182/blood-2019-123629

Published: 2019

Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 1827.

https://doi.org/10.1182/blood-2019-121658

Published: 2019

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Rajshekhar Chakraborty, MBBS, Hien D. Liu, MD, Lisa Rybicki, MS, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Matt Kalaycio, MD, Jack Khouri, MD, Christy J. Samaras, DO, Navneet S. Majhail, MD MS, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2018-99-113114

Published: 2018

Journal Articles

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Sundar Jagannath, MD, Mohit Narang, MD, Sikander Ailawadhi, Robert M Rifkin, MD, Howard R Terebelo, DO, Kathleen Toomey, MD, Brian GM Durie, MD, James W Hardin, PhD, Cristina J Gasparetto, MD, Lynne Wagner, PhD, James Omel, MD, Shankar Srinivasan, PhD MBA, Amani Kitali, MPH, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2018) 132 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2018-99-110877

Published: 2018

Journal Articles

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Gordon Cook, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD, Kwee Yong, PhD, Jamie Cavenagh, MD PhD, John A Snowden, MD, Mark T Drayson, Mamta Garg, David Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M De Tute, BSc,MSc, Roger G. Owen, Cathy Williams, Mark Cook, MBChB,PhD

Blood (2018) 132 (Supplement 1): 255.

https://doi.org/10.1182/blood-2018-99-112116

Published: 2018

Journal Articles

Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

Enrique M. Ocio, MD, Laura Rosinol, MD PhD, Marta Grande, Bachelor's degree, Ana Ruiz-Zorrilla, MD, Alonso Fernandez, PhD MSc, Carmen Montoto, MD

Blood (2018) 132 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2018-99-114430

Published: 2018

Journal Articles

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Blood (2018) 132 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2018-99-113467

Published: 2018

Journal Articles

Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant

Petra Martin, MD, Rebecca Ye, BA, Merle Kolk, Nicole Ferrari, Paolo Caimi, MD, Leland Metheny, MD, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2018-99-113833

Published: 2018

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Evangelos Terpos, MD PhD, Maria Roussou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Despina Fotiou, MD, Dimitrios C. Ziogas, MD, Aristea-Maria Papanota, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Efstathios Kastritis, MD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2018-99-113108

Published: 2018

Journal Articles

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Takeshi Harada, MD PhD, Asuka Oda, PhD, Yohann Grondin, PhD, Jumpei Teramachi, DDS, PhD, Ariunzaya Bat-Erdene, MD PhD, Masami Iwasa, MD, Masahiro Oura, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Shiro Fujii, MD, Hirokazu Miki, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2018-99-114086

Published: 2018

NARROW

A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only